

PATRICK J. KENNEDY  
1ST DISTRICT, RHODE ISLAND

WASHINGTON OFFICE  
407 CANNON HOUSE OFFICE BUILDING  
(202) 225-4911  
FAX: (202) 225-3290  
Email: patrick.kennedy@mail.house.gov

DISTRICT OFFICE  
249 ROOSEVELT AVENUE, SUITE 200  
PAWTUCKET, RI 02860  
(401) 729-5600  
(800) 392-5772  
FAX (401) 729-5608

www.patrickkennedy.house.gov



**Congress of the United States**  
**House of Representatives**  
**Washington, DC 20515**

February 11, 2008

COMMITTEE ON APPROPRIATIONS  
SUBCOMMITTEE ON LABOR, HEALTH  
AND HUMAN SERVICES AND  
EDUCATION  
SUBCOMMITTEE ON SCIENCE, STATE,  
JUSTICE AND COMMERCE  
FOUNDER AND VICE-CHAIRMAN  
NATIVE AMERICAN CAUCUS  
FOUNDER AND CO-CHAIRMAN  
PORTUGUESE-AMERICAN CAUCUS  
FOUNDER AND CO-CHAIRMAN  
21<sup>ST</sup> CENTURY HEALTH CARE CAUCUS  
LAW ENFORCEMENT CAUCUS

Commissioner Andrew C. von Eschenbach, M.D.  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

Dear Dr. von Eschenbach:

I am writing in strong support of the Citizen Petition submitted by The Alliance Against Alveolar Soft Part Sarcoma ("TAAASPS") and the Sarcoma Foundation of America ("SFA") (FDA docket number 2007P-0420). The TAAASPS and SFA Citizen Petition requests that FDA issue a guidance document for the accelerated approval of drugs and biologics that are intended to treat rare cancers.

The Citizen Petition asks the Agency to provide guidelines for the approval of any drug or biological product that is intended to treat a rare cancer, but for which large size studies may not be feasible due to the rarity of the cancer or ethical constraints in conducting such studies. As described in the Citizen Petition, rare cancers affect a small percentage of the U.S. population. Because of the rarity of the cancer, clinical trials, especially those requiring the sponsor to demonstrate a survival benefit, are often difficult to conduct and complete. However, under the Agency's current approval process, such studies are usually necessary to the approval of the product. As a result, drug companies typically avoid the risk of development, and many people affected by rare cancers are left without a viable therapeutic treatment option.

By providing a guidance document concerning the realistic pathway to approval of treatments for rare cancers, FDA can pave the way for companies to continue to develop and seek approval of products intended to treat rare cancers, and to ensure that these products reach patients who desperately need them.

I urge the Agency to act on the Citizen Petition's request and provide needed guidelines for the approval of drug and biologics intended to treat rare cancers, in accordance with all applicable rules and regulations. These guidelines can help preserve and promote public health by making products available to persons suffering from a rare cancer.

Sincerely,

A handwritten signature in black ink that reads "Patrick J. Kennedy".

Patrick J. Kennedy  
Member of Congress

Printed on Recycled Paper